ABC | Volume 110, Nº1, Janeiro 2018

Artigo Original Fischer et al Polimorfismos e extensão da doença coronária Arq Bras Cardiol. 2018; 110(1):16-23 1. WorldHealthOrganization. (WHO). The top ten causes of death. [Accessed in 2017 May 17]. Available from: http://www.who.int/mediacentre/ factsheets/fs310/en/ 2. NgM,FlemingT,RobinsonM,ThomsonB,GraetzN,MargonoC,etal.Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of DiseaseStudy2013.Lancet.2014;384(9945):766-81.doi:10.1016/S0140- 6736(14)60460-8. Erratum in: Lancet. 2014 Aug 30;384(9945):746. 3. ReavenGM.SyndromeX:6years later. J InternMedSuppl.1994;736:13-22. PMID: 7986303. 4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel onDetection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. PMID: 11368702. 5. LakkaHM,LaaksonenDE,LakkaTA,NiskanenLK,KumpusaloE,Tuomilehto J,etal.Themetabolicsyndromeandtotalandcardiovasculardiseasemortality in middle-agedmen. JAMA. 2002;288(21):2709-16. PMID: 12460094. 6. Novo S, Peritore A, Guarneri FP, Corrado E, Macaione F, Evola S, et al. Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up. A prospective study. Atherosclerosis. 2012;223(2):468-72. doi: 10.1016/j.atherosclerosis.2012.05.018. 7. Sinha SK, Goel A, Madaan A, Thakur R, Krishna V, Singh K, et al. Prevalence of metabolic syndrome and its clinical and angiographic profile in patients with naive acute coronary syndrome inNorth Indian population. J ClinMed Res. 2016;8(9):667-73. doi: 10.14740/jocmr2655w. 8. Monteiro CM, Oliveira L, Izar MC, Helfenstein T, Santos AO, Fischer SM, et al. Early glucometabolic profile in patients with acute coronary syndromes and metabolic syndrome. Arq Bras Cardiol. 2009;92(2):89-99. doi: http:// dx.doi.org/10.1590/S0066-782X2009000200004. 9. Monteiro CM, Pinheiro LF, Izar MC, Barros SW, Vasco MB, Fischer SM, et al. Highly sensitive C-reactive protein and male gender are independently related to the severity of coronary disease in patients with metabolic syndrome and an acute coronary event. Braz J Med Biol Res. 2010;43(3):297-302. doi: http://dx.doi.org/10.1590/S0100- 879X2010005000008. 10. Santos AO, Fonseca FA, Fischer SM, Monteiro CM, Brandão SA, Póvoa RM, et al. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Clin Chim Acta. 2009;406(1-2):113-8. doi: 10.1016/j.cca.2009.06.005. 11. Izar MC, Fonseca HA, Pinheiro LF, Monteiro CM, Póvoa RM, Monteiro AM, et al. Adaptive immunity is related to coronary artery disease severity after acute coronary syndrome in subjects with metabolic syndrome. Diab Vasc Dis Res. 2013;10(1):32-9. doi: 10.1177/1479164112443374. 12. Izar MC, Helfenstein T, Ihara SS, Relvas WG, Santos AO, Fischer SC, et al; GOLD Investigators. Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes: the genetics, outcomes, and lipids in type 2 diabetes (GOLD) study. Atherosclerosis. 2009;204(1):165- 70. doi: 10.1016/j.atherosclerosis.2008.08.006. 13. Kaur R, Matharoo K, Sharma R, Bhanwer AJ. C-reactive protein + 1059 G>C polymorphism in type 2 diabetes and coronary artery disease patients. Meta Gene. 2013;1:82-92. doi: 10.1016/j.mgene.2013.10.012. 14. Song Z, Cao H, Qin L, Jiang Y. A case-control study between gene polymorphisms of polyunsaturated fatty acid metabolic rate-limiting enzymes and acute coronary syndrome inChineseHan population. Biomed Res Int. 2013;2013:928178. doi: 10.1155/2013/928178. 15. Palmer BR, Slow S, Ellis KL, Pilbrow AP, Skelton L, Frampton CM, et al. Genetic polymorphism rs6922269 in the MTHFD1L gene is associated with survival and baseline active vitamin B12 levels in post-acute coronary syndromes patients. PLoS One. 2014;9(3):e89029. doi: 10.1371/journal. pone.0089029. 16. Ellis KL, Zhou Y, Beshansky JR, Ainehsazan E, Selker HP, Cupples LA, et al. Genetic modifiers of response to glucose-insulin-potassium (GIK) infusion in acute coronary syndromes and associations with clinical outcomes in the IMMEDIATE trial. Pharmacogenomics J. 2015;15(6):488-95. doi: 10.1038/tpj.2015.10. 17. Ference BA. Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. Curr Opin Lipidol. 2015;26(6):566-71. doi: 10.1097/MOL.0000000000000247. 18. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, LanktreeMB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539-50. doi: 10.1093/eurheartj/eht571. 19. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovasculardisease:Newinsightsfromepidemiology,genetics,andbiology. Circ Res. 2016;118(4):547-63. doi: 10.1161/CIRCRESAHA.115.306249. 20. Jia EZ, Chen ZH, An FH, Li LH, Li-Li, Guo CY, et al. Relationship of renin-angiotensin-aldosterone system polymorphisms and phenotypes to mortality in Chinese coronary atherosclerosis patients. Sci Rep. 2014;4:4600. doi: 10.1038/srep04600. 21. Osadnik T, Strzelczyk JK, LekstonA, Reguła R, Bujak K, FronczekM, et al. The association of functional polymorphisms in genes encoding growth factors for endothelial cells and smooth muscle cells with the severity of coronary artery disease. BMC Cardiovasc Disord. 2016;16(1):218. doi: 10.1186/ s12872-016-0402-4. Referências Fonseca FAH, Izar MCO; Análise estatística: Bianco HT, Monteiro CMC, Pinheiro LFM, Fonseca FAH, Izar MCO; Obtenção de financiamento: IzarMCO; Redação domanuscrito: Fischer SCPM, Fonseca FAH, Izar MCO. Potencial conflito de interesses Declaro não haver conflito de interesses pertinentes. Fontes de financiamento O presente estudo foi financiado pela FAPESP, processo nº 2004/00325-8. Vinculação acadêmica Este artigo é parte de dissertação de Mestrado de Simone Cristina Pinto Matheus Fischer pela Universidade Federal de São Paulo. Aprovação Ética e consentimento informado Este estudo foi aprovado peloComitê de Ética daUniversidade Federal de São Paulo (CEPUNIFESP) sob o número de protocolo CEP 0283/11. Todos os procedimentos envolvidos nesse estudo estão de acordo com a Declaração de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes incluídos no estudo. 22